Program Schedule

107
Clinical - Clinical Trials

Friday, October 10, 2014: 12:30 PM-2:00 PM
Room: The Pennsylvania Convention Center: IDExpo Hall BC

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Health care workers, HIV clinicians, HIV specialists, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists, Vaccinologists

Tracks: Adult ID, Epidemiology and Infection Control, Global ID, HIV-STD-TB, Investigative ID, Pediatric ID

Presentations:
818
Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients, by Baseline Demographics
Ronald Nahass, MD, FIDSA, FSHEA ; John Vierling, MD ; Hans Van Vlierberghe, MD ; David Wyles, MD ; Maurizia Brunetto, MD ; Wangang Xie, PhD ; Daniel Cohen, MD ; Yan Luo, MD ; Jeffrey Enejosa, MD
819
Daclatasvir in Combination with Peginterferon Alfa-2a and Ribavirin for Treatment-Naive Patients with HCV Genotype 4 Infection: Phase 3 COMMAND-4 Results
Christophe Hézode, MD, PhD ; Laurent Alric, MD, PhD ; Ashley Brown, MD ; Tarek Hassanein, MD ; Mario Rizzetto, MD ; Maria Buti, MD ; Marc Bourliere, MD ; Dominique Thabut, MD ; Esther Molina, MD ; Fiona Mcphee, PhD ; Zhaohui Liu, PhD ; Philip Yin, MD, PhD ; Eric Hughes, MD, PhD ; Michelle Treitel, PhD
820
Triple Combination Treatment With Peginterferon Lambda-1a, Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b
Maurizia Brunetto, MD ; Khurram Rana ; Gloria Taliani ; Eric Lawitz ; Christophe Hézode ; Patrick Marcellin ; Lawrence Serfaty ; David Cohen ; Subasree Srinivasan
821
Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results
Donald M. Jensen, MD ; Kenneth Sherman, MD ; Christophe Hezode ; Stanislas Pol ; Stefan Zeuzem, MD ; Victor De Ledinghen, MD ; Albert Tran ; Magdy Elkhashab ; Ziad H Younes ; Marcelo Kugelmas ; Stefan Mauss, MD ; Gregory T. Everson ; Velimir Luketic ; John Vierling, MD ; Lawrence Serfaty ; Maurizia Brunetto, MD ; Jeong Heo ; David Bernstein ; Fiona Mcphee, PhD ; Delphine Hennicken ; Patricia Mendez ; Eric Hughes, MD, PhD ; Stephanie Noviello
822
Effect of Steady State Daclatasvir Plus Asunaprevir on the Single Dose Pharmacokinetics of the P-glycoprotein Substrate Digoxin in Healthy Adult Subjects
Tushar Garimella, PhD ; Robert Adamczyk ; Michele Stonier ; Hamza Kandoussi, MSc ; Michael Hesney ; Elizabeth Colston ; Timothy Eley, PhD ; Marc Bifano, MS
823
Evaluation of Drug-Drug Interaction between Asunaprevir and Methadone or Buprenorphine/Naloxone
Tushar Garimella, PhD ; Timothy Eley, PhD ; Bing He, PhD. ; Wen-Lin Luo, PhD, MSc ; Jane Crowell, RN ; Hamza Kandoussi, MSc ; Michael Demicco, MD ; Elizabeth Colston ; Richard Bertz, PhD ; Marc Bifano, MS
824
An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis
Francisco M. Marty ; John R. Perfect ; Oliver a. Cornely ; Kathleen M. Mullane ; Galia Rahav ; Misun Lee ; Masanori Ito ; Rochelle Maher ; Bernhardt Zeiher ; Luis Ostrosky-Zeichner
825
A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (IMD): Outcomes in Patients with Pulmonary Infections
Issam Raad ; Kathleen M. Mullane ; Dominik Selleslag ; George Thompson ; Dionissios Neofytos, MD ; Shmuel Shoham, MD ; Misun Lee ; Rochelle Maher ; Bernhardt Zeiher ; Francisco M. Marty
827
The efficacy of single dose peramivir in acute uncomplicated influenza: an integrated subject-level meta-analysis
Richard Whitley, MD, FIDSA ; Phil Collis, PhD ; Sylvia Dobo, MD ; Jenna Elder, PhD ; Shigeru Kohno, MD, PhD ; William Sheridan, MB BS

CME Credits:

ACPE Credits:

ACPE Number:


Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek